[Experiences with the tumor markers Ca 125 and plasma ribonuclease in ovarian cancer].
The tumor markers Ca 125 and serum ribonuclease were determined simultaneously in 35 patients with primary ovarian cancer during therapy and follow-up. In patients with second-look operation, Ca 125 and ribonuclease correlated well with the presence of metastases. In our experience the marker Ca 125 appeared to be superior to serum ribonuclease levels. Recurrence may be detected equally well with both markers.
D000230:Adenocarcinoma / Q000473:pathology* / Q000628:therapy; D000951:Antigens, Neoplasm / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor / Q000032:analysis*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006106:Granulosa Cell Tumor / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000628:therapy; D010053:Ovary / Q000473:pathology; D012260:Ribonucleases / Q000097:blood*
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D012260:Ribonucleases
Erfahrungen mit den Tumormarkern Ca 125 und Plasma-Ribonuklease beim Ovarialkarzinom.